Charlotte’s Web has signed an exclusive distribution agreement in Israel with Israel-based InterCure, which owns one of Israel’s largest and most established medical cannabis producers, Canndoc.
Canndoc has been a pioneer in pharmaceutical-grade cannabis for more than 13 years. Its GMP-approved medical cannabis products are sold in pharmacies in Israel, and it holds international cultivation and distribution agreements in the European Union.
Selected Charlotte’s Web hemp extract wellness products will be available to the Israeli public through Canndoc or another subsidiary of InterCure. Charlotte’s Web and InterCure also are considering future distribution agreements in certain European countries. The two companies will also explore opportunities such as clinical trials, product development and manufacturing in Israel.
Founded in 2008, Canndoc is an IMCA (Israeli Medical Cannabis Agency) permit holder for the manufacturing of medical cannabis in Israel. Canndoc has provided medical cannabis for more than 40,000 patients, establishing its position as a venerable player in this global industry, demonstrating significant expertise across the entire value chain from research, cultivation, and processing, to product development and advanced GMP clinical trials pipeline initiation.
The sale of CBD is reportedly on the verge of being legalized in Israel. The two companies have agreed to cooperate in order to supply the Israeli market, once that occurs, with the highest quality and most trusted CBD wellness products in the world.
As a result of this Agreement, InterCure will become one of Charlotte’s Web’s leading strategic allies outside of North America.
For more information:
Charlotte's Web Holdings